{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:52Z","timestamp":1785595912073,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00520-024-09006-z","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:52:21Z","timestamp":1732701141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment"],"prefix":"10.1007","volume":"32","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"9006_CR1","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M et al (2023) Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 41:1992\u20131998","journal-title":"J Clin Oncol"},{"key":"9006_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M et al (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756\u2013763","journal-title":"J Thorac Oncol"},{"key":"9006_CR3","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"JD Patel","year":"2013","unstructured":"Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR et al (2013) PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31:4349\u20134357","journal-title":"J Clin Oncol"},{"key":"9006_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211","journal-title":"Lancet Oncol"},{"key":"9006_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K et al (2023) Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol 41:1213\u20131227","journal-title":"J Clin Oncol"},{"key":"9006_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M et al (2023) Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol 9:527\u2013535","journal-title":"JAMA Oncol"},{"key":"9006_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40262-020-00972-1","volume":"60","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ et al (2021) Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. Clin Pharmacokinet 60:649\u2013654","journal-title":"Clin Pharmacokinet"},{"key":"9006_CR8","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"9006_CR9","doi-asserted-by":"crossref","unstructured":"Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T et al (2023) Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28:1259\u20131297","DOI":"10.1007\/s10147-023-02372-4"},{"key":"9006_CR10","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. PEMETREXED FOR INJECTION. Zydus Hospira Oncology Private Ltd. June 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208746s000lbl.pdf. accessed February 16, 2024."},{"key":"9006_CR11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1248\/bpb.b15-00162","volume":"38","author":"H Ikesue","year":"2015","unstructured":"Ikesue H, Watanabe H, Hirano M, Chikamori A, Suetsugu K, Ryokai Y et al (2015) Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. Biol Pharm Bull 38:1192\u20131198","journal-title":"Biol Pharm Bull"},{"key":"9006_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00280-014-2589-3","volume":"74","author":"K Kanazawa","year":"2014","unstructured":"Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S et al (2014) Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy\/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. Cancer Chemother Pharmacol 74:1149\u20131157","journal-title":"Cancer Chemother Pharmacol"},{"key":"9006_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00280-012-1910-2","volume":"70","author":"YH Kim","year":"2012","unstructured":"Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K et al (2012) Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol 70:271\u2013276","journal-title":"Cancer Chemother Pharmacol"},{"key":"9006_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/bjc.1997.509","volume":"76","author":"Y Ando","year":"1997","unstructured":"Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K (1997) Adjustment of creatinine clearance improves accuracy of Calvert\u2019s formula for carboplatin dosing. Br J Cancer 76:1067\u20131071","journal-title":"Br J Cancer"},{"key":"9006_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1248\/yakushi.13-00180","volume":"133","author":"Y Sakata","year":"2013","unstructured":"Sakata Y, Iwamoto Y, Abe K, Miyamori S, Inata J, Kanehara M et al (2013) Analysis of risk factors for severe adverse events of chemotherapy with pemetrexed and comparison of adverse event occurrence according to renal function. Yakugaku Zasshi 133:1209\u20131213","journal-title":"Yakugaku Zasshi"},{"key":"9006_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-016-3078-7","volume":"78","author":"Y Ando","year":"2016","unstructured":"Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K et al (2016) Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol 78:183\u2013189","journal-title":"Cancer Chemother Pharmacol"},{"key":"9006_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3109\/07357900009012191","volume":"18","author":"EC Dees","year":"2000","unstructured":"Dees EC, O\u2019Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ et al (2000) A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521\u2013529","journal-title":"Cancer Invest"},{"key":"9006_CR18","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s00520-021-06757-x","volume":"30","author":"Y Saito","year":"2022","unstructured":"Saito Y, Takekuma Y, Shinagawa N, Sugawara M (2022) Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Support Care Cancer 30:4081\u20134088","journal-title":"Support Care Cancer"},{"key":"9006_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/JCO.2000.18.2.325","volume":"18","author":"E Voog","year":"2000","unstructured":"Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C et al (2000) Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 18:325\u2013331","journal-title":"J Clin Oncol"},{"key":"9006_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M et al (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2:47\u201356","journal-title":"Clin Lymphoma"},{"key":"9006_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdn560","volume":"20","author":"P Jenkins","year":"2009","unstructured":"Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20:34\u201340","journal-title":"Ann Oncol"},{"key":"9006_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","volume":"19","author":"M Schwenkglenks","year":"2011","unstructured":"Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A et al (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 19:483\u2013490","journal-title":"Support Care Cancer"},{"key":"9006_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000355107","volume":"85","author":"M O'Malley","year":"2013","unstructured":"O\u2019Malley M, Healy P, Daignault S, Ramnath N (2013) Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85:216\u2013222","journal-title":"Oncology"},{"key":"9006_CR24","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00520-020-05842-x","volume":"29","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Kobayashi M, Komatsu Y, Sugawara M (2021) Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer 29:3277\u20133285","journal-title":"Support Care Cancer"},{"key":"9006_CR25","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.7314\/APJCP.2014.15.8.3443","volume":"15","author":"WA Kwon","year":"2014","unstructured":"Kwon WA, Oh TH, Lee JW, Park SC (2014) Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration- resistant prostate cancer. Asian Pac J Cancer Prev 15:3443\u20133446","journal-title":"Asian Pac J Cancer Prev"},{"key":"9006_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825\u2013830","journal-title":"Ann Intern Med"},{"key":"9006_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317","journal-title":"Int J Clin Oncol"},{"key":"9006_CR28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"9006_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J et al (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379:2040\u20132051","journal-title":"N Engl J Med"},{"key":"9006_CR30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","volume":"27","author":"EF Smit","year":"2009","unstructured":"Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM et al (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038\u20132045","journal-title":"J Clin Oncol"},{"key":"9006_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.lungcan.2012.07.009","volume":"78","author":"M Tiseo","year":"2012","unstructured":"Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F et al (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78:92\u201399","journal-title":"Lung Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09006-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-09006-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09006-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:05:50Z","timestamp":1733760350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-09006-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9006"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-09006-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of retrospective study, the need for formal consent was waived by the Ethical Review Board for Life Science and Medical Research at Hokkaido University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"829"}}